Lichen Capital

elsewhere's corpus doesn't contain a standalone profile of Lichen Capital (骊宸投资/骊宸资本) — no founding date, team, or fund size is covered. What the material does show is a fund that appears repeatedly as a co-investor in healthcare and biotech rounds: it followed into Oricell Therapeutics' $70M Series C first tranche in early 2026 and again its $110M Pre-IPO round announced April 2026, both led by Qiming Venture Partners alongside the Beijing Healthcare Industry Investment Fund ; it also joined Zhitai Bio's round led by Lanchi Ventures , and backed radiopharmaceuticals company CoreVision Biopharma from its ~RMB 100M angel round in 2022 through its Series A in 2024, per Gaorong's announcements . On that evidence it reads as a life-sciences-oriented investor that typically takes follow-on rather than lead positions, but elsewhere has not covered the firm itself directly.